The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.0<；SUP>；2,11<；/SUP>；.0<；SUP>；4,9<；/SUP>；]-hexadeca-2(11),3,5,7,9-pentaene: and pharmaceutical compositions thereof. The present invention in particular is directed to the L-tartrate salt, and further to the various polymorphs of the L-tartrate salt, including two distinct anhydrous polymorphs (referred to herein as Forms A and B) and a hydrate polymorph (referred to herein as Form C). In addition, the present invention is also directed to the D-tartrate salt of 5,8,14-triazatetracyclo[10.3.1.0<；SUP>；2,11<；/SUP>；.0<；SUP>；4,9<；/SUP>；]-hexadeca-2(11),3,5,7,9-pentaene and the various polymorphs thereof； as well as the D,L-tartrate salt thereof and its polymorphs, and the meso-tartrate salt thereof and its polymorphs.
